Key result
AT2R agonists attenuate hypertension-induced vascular remodeling and reduce arterial stiffening, but do not acutely alter blood pressure in vivo without concurrent AT1R blockade.
Why the study?
Do AT2R-agonistic molecules improve blood pressure regulation and hypertensive end-organ damage in preclinical models?
Population
Preclinical animal and in vitro models relevant for blood pressure regulation or hypertensive end-organ damage
Design
Review
Authors
Loading...
Does not support AT2R agonist monotherapy for BP control; leaves open adjunctive use to limit vascular remodeling in future studies.
Do AT2R-agonistic molecules improve blood pressure regulation and hypertensive end-organ damage in preclinical models?
Preclinical data suggest AT2R agonists may be beneficial in combination with established antihypertensives for improved protection from end-organ damage, rather than as monotherapy.
Steckelings et al. (2013) conducted a review in Hypertension. AT2R agonists (Compound 21 and β-amino acid substituted angiotensin II) was evaluated. AT2R agonists attenuate hypertension-induced vascular remodeling and reduce arterial stiffening, but do not acutely alter blood pressure in vivo without concurrent AT1R blockade.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: